2002年，BioCryst 制药公司宣布，停止对公司正在开发的流感药Peramivir的继续研究。但是现在又开始了对此药物的临床研究，谁知道这是为什么啊？？
原以口服制进行临床试验，2002.3完成的三期临床试验显示因为口服后不能充分进入血液,难以达到明显的治疗效果，临床无效，而放弃继续开发。后改为注射给药，重新进行临床研究。
哦，十分感谢，您是否能告诉我这个品种目前的状态是什么？
以前跟踪过，现没再细查。具体进度你再查查吧。国外05年底开始的临床试验，现应处在临床阶段吧？
2007年10月，国内有1.1类国产申报申报：帕拉米韦三水合物及注射液、输液。
恩，好的，了，建议加分
这是一个很有价值的品种。
Pharmaprojects上的。
peramivir.part1.rar (292.97k)
part2.rar
peramivir.part2.rar (72.64k)
Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability. BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.
US Department of Health and Human Services (2007-01-04). "". Press release. Retrieved on 2007-05-25.
Pollack, Andrew. "", New York Times, 2005-10-07. Retrieved on 2007-05-25.
. National Institutes of Health (2007-03-16). Retrieved on 2007-05-25.
. National Institutes of Health (2007-03-28). Retrieved on 2007-05-25.
另Biocryst Pharmaceuticals公司网站上也有相关信息：
那谁能提供它的理化性质呢？
或者告诉我应该在哪个网站去查！！
原以口服制进行临床试验，2002.3完成的三期临床试验显示因为口服后不能充分进入血液,难以达到明显的治疗效果，临床无效，而放弃继续开发。后改为注射给药，重新进行临床研究。
哦，十分感谢，您是否能告诉我这个品种目前的状态是什么？
以前跟踪过，现没再细查。具体进度你再查查吧。国外05年底开始的临床试验，现应处在临床阶段吧？
2007年10月，国内有1.1类国产申报申报：帕拉米韦三水合物及注射液、输液。
恩，好的，了，建议加分
这是一个很有价值的品种。
Pharmaprojects上的。
peramivir.part1.rar (292.97k)
part2.rar
peramivir.part2.rar (72.64k)
Peramivir is an experimental antiviral drug being developed by Biocryst Pharmaceuticals to treat influenza. Peramivir is a neuraminidase inhibitor, acting as a transition-state analogue inhibitor of influenza neuraminidase and thereby preventing new viruses from emerging from infected cells. The development of peramivir is supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
The drug has had a long history. An oral formulation was abandoned by Johnson and Johnson due to poor bioavailability. BioCryst is now developing a injectable version, in partnership with Green Cross Pharmaceuticals in South Korea and with Shionogi Pharmaceuticals in Japan. The drug is in Phase II studies.
US Department of Health and Human Services (2007-01-04). "". Press release. Retrieved on 2007-05-25.
Pollack, Andrew. "", New York Times, 2005-10-07. Retrieved on 2007-05-25.
. National Institutes of Health (2007-03-16). Retrieved on 2007-05-25.
. National Institutes of Health (2007-03-28). Retrieved on 2007-05-25.
另Biocryst Pharmaceuticals公司网站上也有相关信息：
那谁能提供它的理化性质呢？
或者告诉我应该在哪个网站去查！！